Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy MDGL Stock  Free MDGL Stock Alerts

Madrigal Pharmaceuticals (MDGL) Financials

Madrigal Pharmaceuticals logo
$292.76 +2.04 (+0.70%)
As of 05/20/2025 04:00 PM Eastern
Compare
Annual Income Statements for Madrigal Pharmaceuticals

Annual Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -466 -374 -295 -242 -202 -84 -33 -31 -26 -69
Consolidated Net Income / (Loss)		 -466 -374 -295 -242 -202 -84 -33 -31 -26 -69
Net Income / (Loss) Continuing Operations		 -466 -374 -295 -242 -202 -84 -33 -31 -26 -69
Total Pre-Tax Income 		-466 -374 -295 -242 -202 -84 -33 -31 -26 -69
Total Operating Income		 -498 -380 -294 -242 -207 -95 -41 -32 -25 -68
Total Gross Profit		 174 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 180 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 180 0.00 0.00 - 0.00 0.00 0.00 - - -
Total Cost of Revenue		 6.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 6.23 0.00 0.00 - - - - - - -
Total Operating Expenses		 672 380 294 242 207 95 41 32 25 68
Selling, General & Admin Expense		 435 108 48 37 22 23 15 7.67 9.29 13
Research & Development Expense		 237 272 245 205 185 72 25 24 16 54
Total Other Income / (Expense), net		 32 6.87 -1.78 0.64 4.43 11 7.87 0.91 -1.17 -1.06
Interest Expense		 15 13 3.96 0.00 0.00 - - - 1.21 -
Interest & Investment Income		 47 20 2.19 0.36 4.33 11 7.67 0.56 0.05 -1.06
Basic Earnings per Share		 ($21.90) ($19.99) ($17.23) ($14.63) ($13.09) ($5.45) ($2.22) ($2.54) ($5.07) ($0.53)
Weighted Average Basic Shares Outstanding		 21.27M 18.69M 17.14M 16.54M 15.45M 15.39M 14.80M 12.24M 5.20M 137.81M
Diluted Earnings per Share		 ($21.90) ($19.99) ($17.23) ($14.63) ($13.09) ($5.45) ($2.22) ($2.54) ($5.07) ($0.53)
Weighted Average Diluted Shares Outstanding		 21.27M 18.69M 17.14M 16.54M 15.45M 15.39M 14.80M 12.24M 5.20M 137.81M
Weighted Average Basic & Diluted Shares Outstanding		 22.08M 19.90M 18.14M 16.54M 15.45M 15.39M 14.80M 12.24M 5.20M 128.59M

Quarterly Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Consolidated Net Income / (Loss)		 -73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Net Income / (Loss) Continuing Operations		 -73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Total Pre-Tax Income 		-73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Total Operating Income		 -79 -67 -116 -163 -152 -117 -99 -86 -78 -85 -80
Total Gross Profit		 137 97 62 15 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 137 103 62 15 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 137 - 62 15 - - 0.00 0.00 - - -
Total Cost of Revenue		 0.00 6.23 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 217 164 178 177 152 117 99 86 78 85 80
Selling, General & Admin Expense		 172 138 110 106 81 47 28 18 16 15 12
Research & Development Expense		 44 26 69 71 71 71 71 69 62 71 68
Total Other Income / (Expense), net		 6.07 7.58 9.34 11 4.50 4.98 -0.21 0.65 1.44 -0.61 -0.79
Interest Expense		 3.30 3.50 3.68 3.66 3.84 3.97 3.50 2.90 2.34 1.68 1.50
Interest & Investment Income		 9.37 11 13 14 8.33 8.95 3.30 3.55 3.78 1.08 0.72
Basic Earnings per Share		 ($3.32) ($2.50) ($4.92) ($7.10) ($7.38) ($5.73) ($5.34) ($4.69) ($4.23) ($4.98) ($4.75)
Weighted Average Basic Shares Outstanding		 22.09M 21.27M 21.75M 21.40M 20.00M 18.69M 18.48M 18.31M 18.19M 17.14M 17.10M
Diluted Earnings per Share		 ($3.32) ($2.50) ($4.92) ($7.10) ($7.38) ($5.73) ($5.34) ($4.69) ($4.23) ($4.98) ($4.75)
Weighted Average Diluted Shares Outstanding		 22.09M 21.27M 21.75M 21.40M 20.00M 18.69M 18.48M 18.31M 18.19M 17.14M 17.10M
Weighted Average Basic & Diluted Shares Outstanding		 22.20M 22.08M 21.81M 21.71M 21.31M 19.90M 19.74M 18.47M 18.29M 18.14M 17.10M

Annual Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 5.10 -232 295 -18 7.31 -11 -91 129 19 0.16
Net Cash From Operating Activities		 -456 -324 -225 -184 -158 -42 -26 -22 -18 -3.14
Net Cash From Continuing Operating Activities		 -456 -324 -225 -184 -158 -42 -26 -22 -18 -3.14
Net Income / (Loss) Continuing Operations		 -466 -374 -295 -242 -202 -84 -33 -31 -26 -6.84
Consolidated Net Income / (Loss)		 -466 -374 -295 -242 -202 -84 -33 -31 -26 -6.84
Depreciation Expense		 1.10 0.53 0.47 0.41 0.47 0.11 0.10 0.08 0.00 -
Amortization Expense		 1.69 2.41 0.80 0.00 0.00 - - - - -
Non-Cash Adjustments To Reconcile Net Income		 56 44 32 28 23 26 9.82 3.25 9.89 3.61
Changes in Operating Assets and Liabilities, net		 -48 2.17 38 30 22 16 -2.61 5.51 -1.11 0.09
Net Cash From Investing Activities		 -274 -503 207 -5.06 160 31 -380 -22 22 0.00
Net Cash From Continuing Investing Activities		 -274 -503 207 -5.06 160 31 -380 -22 22 0.00
Purchase of Property, Plant & Equipment		 -1.46 -1.48 -0.22 -0.21 -0.33 -0.17 -0.02 -0.13 -0.00 -
Acquisitions		 -5.00 0.00 0.00 - - - - - - -
Purchase of Investments		 -1,131 -834 -143 -394 -329 -619 -614 -70 -11 -
Sale and/or Maturity of Investments		 863 333 350 389 489 650 234 48 26 -
Net Cash From Financing Activities		 735 595 313 171 5.09 0.24 314 174 14 3.30
Net Cash From Continuing Financing Activities		 735 595 313 171 5.09 0.24 314 174 14 3.30
Repayment of Debt		 0.00 -0.36 -0.89 0.00 0.00 - - - - -
Issuance of Debt		 0.00 65 50 0.00 0.00 - - - 8.50 2.80
Issuance of Common Equity		 735 530 264 171 4.42 - - - 0.00 0.00

Quarterly Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 84 -133 -262 -123 523 38 -15 -36 -218 272 6.07
Net Cash From Operating Activities		 -89 -104 -67 -135 -149 -80 -85 -75 -84 -59 -59
Net Cash From Continuing Operating Activities		 -89 -105 -67 -135 -149 -80 -85 -75 -84 -59 -59
Net Income / (Loss) Continuing Operations		 -73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Consolidated Net Income / (Loss)		 -73 -59 -107 -152 -148 -112 -99 -86 -77 -86 -81
Depreciation Expense		 0.38 0.36 0.30 0.27 0.17 0.14 0.14 0.13 0.12 0.13 0.12
Amortization Expense		 0.49 0.08 0.48 0.47 0.66 0.75 0.67 0.55 0.43 0.31 0.31
Non-Cash Adjustments To Reconcile Net Income		 24 4.34 18 15 19 13 13 9.58 9.08 8.50 7.80
Changes in Operating Assets and Liabilities, net		 -40 -50 21 1.76 -21 19 -0.08 0.23 -17 18 14
Net Cash From Investing Activities		 164 -48 -202 -122 98 -362 50 -3.73 -187 66 65
Net Cash From Continuing Investing Activities		 164 -48 -202 -122 98 -362 50 -3.73 -187 66 65
Purchase of Property, Plant & Equipment		 0.00 -0.20 -0.78 -0.13 -0.36 -1.04 -0.34 -0.07 -0.04 -0.03 -0.03
Acquisitions		 0.00 - - - - - - - - - -
Purchase of Investments		 -131 -350 -416 -281 -84 -475 -69 -92 -199 -13 -14
Sale and/or Maturity of Investments		 295 302 214 164 183 114 119 88 12 79 79
Net Cash From Financing Activities		 8.64 20 7.46 134 574 480 20 43 53 264 -
Net Cash From Continuing Financing Activities		 8.64 20 7.46 134 574 480 20 43 53 264 -
Issuance of Common Equity		 8.64 20 7.46 134 574 480 4.66 28 18 - -

Annual Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 1,042 641 363 273 287 442 485 192 41 0.36
Total Current Assets		 1,033 637 361 272 285 440 485 192 41 0.36
Cash & Equivalents		 100 100 332 36 54 47 57 149 19 0.31
Restricted Cash		 5.00 0.00 - - - - - - - -
Short-Term Investments		 826 534 27 234 230 392 426 43 21 -
Accounts Receivable		 54 0.00 - - - - - - - 0.01
Inventories, net		 34 0.00 - - - - - - - -
Prepaid Expenses		 14 3.15 2.60 1.34 1.01 1.15 1.48 0.49 0.71 0.05
Plant, Property, & Equipment, net		 2.19 1.55 0.60 0.85 1.05 1.18 0.23 0.30 0.00 0.00
Total Noncurrent Assets		 7.13 1.71 0.60 0.80 0.79 0.68 0.00 0.00 0.00 0.00
Intangible Assets		 4.73 0.00 - - - - - - - -
Other Noncurrent Operating Assets		 2.40 1.71 0.60 0.80 0.79 0.68 - - - -
Total Liabilities & Shareholders' Equity		 1,042 641 363 273 287 442 485 192 41 0.36
Total Liabilities		 288 235 165 77 47 25 8.44 10 4.80 49
Total Current Liabilities		 169 119 116 77 47 25 8.44 10 4.80 49
Accounts Payable		 44 28 24 21 1.02 1.18 2.49 1.93 0.76 0.10
Accrued Expenses		 125 90 91 55 45 24 5.96 8.13 4.04 0.07
Other Current Liabilities		 0.98 0.53 0.60 0.41 0.32 0.32 - - - -
Total Noncurrent Liabilities		 119 117 49 0.39 0.47 0.36 0.00 0.00 0.00 0.00
Long-Term Debt		 118 115 49 0.00 - - - - - -
Other Noncurrent Operating Liabilities		 1.02 1.19 0.00 0.39 0.47 0.36 - - - -
Total Equity & Noncontrolling Interests		 754 405 197 196 240 417 477 182 36 -49
Total Preferred & Common Equity		 754 405 197 196 240 417 477 182 36 -49
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 754 405 197 196 240 417 477 182 36 -49
Common Stock		 2,556 1,741 1,160 863 665 640 617 289 112 0.01
Retained Earnings		 -1,802 -1,336 -963 -667 -425 -223 -139 -106 -75 -49
Accumulated Other Comprehensive Income / (Loss)		 0.47 0.47 -0.03 -0.08 0.05 0.22 -0.32 -0.03 0.03 -

Quarterly Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 997 1,073 1,100 1,082 238 302 332 159
Total Current Assets		 988 1,064 1,092 1,074 235 302 331 157
Cash & Equivalents		 184 233 495 623 62 77 113 59
Restricted Cash		 5.00 5.00 5.00 - - - - -
Short-Term Investments		 659 766 563 437 170 221 216 94
Accounts Receivable		 61 30 6.90 - - - - -
Inventories, net		 55 8.72 7.07 0.85 - - - -
Prepaid Expenses		 23 21 15 14 3.12 3.18 1.81 3.92
Plant, Property, & Equipment, net		 1.90 2.27 1.70 1.74 0.66 0.46 0.51 0.70
Total Noncurrent Assets		 6.75 7.33 6.37 6.59 1.84 0.41 0.65 0.83
Intangible Assets		 4.64 4.82 4.91 5.00 - - - -
Other Noncurrent Operating Assets		 2.11 2.51 1.46 1.59 1.84 0.41 0.65 0.83
Total Liabilities & Shareholders' Equity		 997 1,073 1,100 1,082 238 302 332 159
Total Liabilities		 286 296 243 232 216 199 182 148
Total Current Liabilities		 167 178 125 114 100 100 98 99
Accounts Payable		 42 46 8.99 22 17 18 12 19
Accrued Expenses		 124 131 116 92 83 82 86 80
Other Current Liabilities		 1.02 0.88 0.56 0.54 0.51 0.41 0.65 0.76
Total Noncurrent Liabilities		 119 118 118 117 116 99 84 49
Long-Term Debt		 118 117 117 116 115 99 84 49
Other Noncurrent Operating Liabilities		 0.75 1.18 0.90 1.05 1.32 - - 0.07
Total Equity & Noncontrolling Interests		 711 777 857 851 22 104 150 11
Total Preferred & Common Equity		 711 777 857 851 22 104 150 11
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 711 777 857 851 22 104 150 11
Common Stock		 2,586 2,519 2,493 2,335 1,246 1,229 1,190 888
Retained Earnings		 -1,875 -1,743 -1,636 -1,484 -1,224 -1,125 -1,040 -877
Accumulated Other Comprehensive Income / (Loss)		 0.39 1.27 -0.37 -0.17 -0.04 -0.09 -0.09 -0.24

Annual Metrics And Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -31.13% -29.16% -20.89% -17.32% -117.27% -134.88% -27.66% -25.42% 0.00% 18.81%
EBIT Growth		 -30.85% -29.61% -21.21% -17.25% -117.51% -134.60% -27.66% -25.73% 0.00% 19.46%
NOPAT Growth		 -30.85% -29.61% -21.07% -17.33% -117.61% -133.45% -26.89% -27.11% 0.00% 19.46%
Net Income Growth		 -24.69% -26.50% -22.12% -19.58% -140.92% -155.85% -5.32% -18.06% 0.00% 20.30%
EPS Growth		 -9.55% -16.02% -17.77% -11.76% -140.18% -145.50% 12.60% 49.90% 0.00% 39.08%
Operating Cash Flow Growth		 -40.51% -44.19% -22.26% -16.73% -278.53% -63.19% -14.29% -26.74% -460.44% 96.02%
Free Cash Flow Firm Growth		 -51.83% -58.15% -20.02% -13.58% -142.38% -63.60% -79.62% 0.00% 0.00% -10.57%
Invested Capital Growth		 47.67% -1.09% -50.99% -68.04% -96.53% -233.83% 27.34% -126.60% 0.00% 96.65%
Revenue Q/Q Growth		 134.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 9.13% -9.08% -7.49% -2.14% -16.65% -19.53% 0.00% 0.00% 0.00% -11.55%
EBIT Q/Q Growth		 9.16% -9.14% -7.59% -2.13% -16.66% -19.50% 0.00% 0.00% 0.00% -11.55%
NOPAT Q/Q Growth		 9.16% -9.14% -7.59% -2.13% -16.72% -19.50% 0.00% 0.00% 0.00% -11.55%
Net Income Q/Q Growth		 10.18% -7.57% -7.79% -2.30% -18.37% -24.03% 0.00% 0.00% 0.00% -9.60%
EPS Q/Q Growth		 12.85% -3.90% -7.35% 0.14% -18.25% -23.58% 0.00% 0.00% 0.00% 93.87%
Operating Cash Flow Q/Q Growth		 -5.70% -7.07% -4.88% 3.61% -37.13% -16.90% -1.27% -3.07% -31.17% 85.22%
Free Cash Flow Firm Q/Q Growth		 -8.90% -9.47% -3.65% 5.74% -35.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 45.79% -18.81% -19.84% -15.52% 4.44% -69.52% 0.00% 0.00% 0.00% 97.01%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 96.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -274.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -276.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -276.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -258.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.58% 98.20% 100.61% 99.85% 97.90% 88.39% 81.05% 98.24% 104.62% 101.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -80.35% -123.98% -150.12% -110.92% -61.61% -18.79% -9.95% -28.49% 422.09% -846.61%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -59.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -55.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -80.35% -123.98% -150.12% -110.92% -61.61% -18.79% -9.95% -28.49% 422.09% -846.61%
Return on Equity Simple (ROE_SIMPLE)		 -61.76% -92.18% -149.63% -123.32% -84.28% -20.15% -6.88% -17.09% -72.47% 140.39%
Net Operating Profit after Tax (NOPAT)		 -349 -266 -205 -170 -145 -66 -28 -22 -18 -47
NOPAT Margin		 -193.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -17.62% -25.91% -30.99% -26.01% -15.92% -3.79% -1.28% -7.51% -21.56% -120.26%
Return On Investment Capital (ROIC_SIMPLE)		 -39.97% -51.14% -83.31% - - - - - - 14,873.68%
Cost of Revenue to Revenue		 3.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 241.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 131.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 372.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -498 -380 -294 -242 -207 -95 -40 -32 -25 -68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -495 -378 -292 -242 -206 -95 -40 -32 -25 -68
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 8.92 11.27 25.15 7.39 7.17 3.37 3.64 6.29 4.73 0.00
Price to Tangible Book Value (P/TBV)		 8.98 11.27 25.15 7.39 7.17 3.37 3.64 6.29 4.73 0.00
Price to Revenue (P/Rev)		 37.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 32.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.16 0.28 0.25 0.00 0.00 0.00 0.00 0.00 0.00 -0.99
Long-Term Debt to Equity		 0.16 0.28 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.15 -1.37 -1.47 -1.27 -1.10 -1.03 -1.02 -1.06 -1.11 -2.19
Leverage Ratio		 1.45 1.66 1.62 1.28 1.11 1.04 1.03 1.07 -3.33 6.23
Compound Leverage Factor		 1.36 1.63 1.63 1.28 1.09 0.92 0.83 1.05 -3.48 6.33
Debt to Total Capital		 13.48% 22.17% 19.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15,272.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15,272.23%
Long-Term Debt to Total Capital		 13.48% 22.17% 19.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 86.52% 77.83% 80.02% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 15,372.23%
Debt to EBITDA		 -0.24 -0.31 -0.17 0.00 0.00 0.00 0.00 0.00 0.00 -0.72
Net Debt to EBITDA		 1.64 1.37 1.06 0.00 0.00 0.00 0.00 0.00 0.00 -0.71
Long-Term Debt to EBITDA		 -0.24 -0.31 -0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.34 -0.43 -0.24 0.00 0.00 0.00 0.00 0.00 0.00 -1.03
Net Debt to NOPAT		 2.33 1.95 1.51 0.00 0.00 0.00 0.00 0.00 0.00 -1.02
Long-Term Debt to NOPAT		 -0.34 -0.43 -0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.20 7.74 12.46 5.77 18.49 32.80 123.79 68.27 18.03 -962.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.10 5.38 3.12 3.54 6.13 17.52 57.46 19.10 8.58 0.01
Quick Ratio		 5.79 5.35 3.10 3.52 6.10 17.47 57.29 19.05 8.44 0.01
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -403 -265 -168 -140 -123 -51 -31 -17 0.00 -65
Operating Cash Flow to CapEx		 -31,160.88% -21,922.24% -103,620.74% -87,998.56% -47,173.95% -24,200.00% -115,940.91% -17,853.60% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -27.44 -20.86 -42.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -31.05 -25.51 -56.72 0.00 0.00 0.00 0.00 0.00 -14.52 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -31.15 -25.62 -56.78 0.00 0.00 0.00 0.00 0.00 -13.94 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 96.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,097.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -2,097.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -59 -113 -112 -74 -44 -22 -6.73 -9.27 -4.09 -0.62
Invested Capital Turnover		 -2.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 54 -1.22 -38 -30 -22 -16 2.53 -5.18 0.00 18
Enterprise Value (EV)		 5,916 4,049 4,655 1,178 1,435 967 1,251 955 132 97
Market Capitalization		 6,730 4,568 4,964 1,449 1,719 1,406 1,735 1,147 172 49
Book Value per Share		 $34.59 $20.53 $11.54 $11.47 $15.52 $27.00 $30.99 $14.59 $3.15 ($0.36)
Tangible Book Value per Share		 $34.37 $20.53 $11.54 $11.47 $15.52 $27.00 $30.99 $14.59 $3.15 ($0.36)
Total Capital		 872 521 247 196 240 417 477 182 36 -0.32
Total Debt		 118 115 49 0.00 0.00 0.00 0.00 0.00 0.00 49
Total Long-Term Debt		 118 115 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -814 -519 -309 -270 -284 -439 -484 -192 -41 48
Capital Expenditures (CapEx)		 1.46 1.48 0.22 0.21 0.33 0.17 0.02 0.13 -0.70 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -68 -115 -113 -76 -46 -24 -6.96 -9.57 -4.09 -0.62
Debt-free Net Working Capital (DFNWC)		 864 519 245 195 239 415 477 182 36 -0.32
Net Working Capital (NWC)		 864 519 245 195 239 415 477 182 36 -49
Net Nonoperating Expense (NNE)		 117 107 90 72 58 17 4.33 8.71 8.73 21
Net Nonoperating Obligations (NNO)		 -814 -519 -309 -270 -284 -439 -484 -192 -41 48
Total Depreciation and Amortization (D&A)		 2.79 2.94 1.26 0.41 0.47 0.11 0.10 0.08 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -37.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 479.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 479.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($21.90) ($19.99) $0.00 $0.00 $0.00 ($5.45) ($2.22) ($2.54) ($5.07) ($18.55)
Adjusted Weighted Average Basic Shares Outstanding		 21.27M 18.69M 0.00 0.00 0.00 15.43M 15.42M 14.23M 12.17M 3.94M
Adjusted Diluted Earnings per Share		 ($21.90) ($19.99) $0.00 $0.00 $0.00 ($5.45) ($2.22) ($2.54) ($5.07) ($18.55)
Adjusted Weighted Average Diluted Shares Outstanding		 21.27M 18.69M 0.00 0.00 0.00 15.43M 15.42M 14.23M 12.17M 3.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($5.45) ($2.22) ($2.54) ($5.07) ($18.55)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.08M 19.90M 0.00 0.00 0.00 15.39M 14.80M 12.24M 5.20M 3.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -349 -266 -205 -170 -145 -66 -28 -22 -18 -47
Normalized NOPAT Margin		 -193.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -258.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -33.94 -29.93 -74.06 0.00 0.00 0.00 0.00 0.00 -20.79 0.00
NOPAT to Interest Expense		 -23.76 -20.95 -51.84 0.00 0.00 0.00 0.00 0.00 -14.56 0.00
EBIT Less CapEx to Interest Expense		 -34.04 -30.05 -74.11 0.00 0.00 0.00 0.00 0.00 -20.22 0.00
NOPAT Less CapEx to Interest Expense		 -23.85 -21.07 -51.90 0.00 0.00 0.00 0.00 0.00 -13.98 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 48.13% 42.77% -18.22% -88.64% -94.41% -37.02% -22.19% -22.55% -35.31% -31.58% -26.82%
EBIT Growth		 47.83% 42.82% -18.03% -88.01% -94.08% -37.37% -22.54% -23.02% -36.03% -32.04% -27.31%
NOPAT Growth		 47.83% 42.82% -18.03% -88.01% -94.08% -37.37% -22.54% -23.02% -36.03% -32.04% -27.31%
Net Income Growth		 50.36% 47.04% -8.33% -77.12% -91.87% -30.60% -21.61% -21.31% -33.69% -33.08% -28.68%
EPS Growth		 55.01% 56.37% 7.87% -51.39% -74.47% -15.06% -12.42% -13.29% -25.89% -31.05% -25.33%
Operating Cash Flow Growth		 40.40% -30.72% 21.12% -79.19% -77.43% -36.60% -43.76% -31.29% -68.43% -21.78% -29.66%
Free Cash Flow Firm Growth		 -16.99% -24.90% -0.39% -171.03% -225.63% -269.76% -148.54% -94.58% -163.59% -44.14% -3.17%
Invested Capital Growth		 78.92% 47.67% -14.69% 6.90% 3.36% -1.09% -1.96% -20.24% -28.52% -50.99% -45.56%
Revenue Q/Q Growth		 32.84% 66.18% 324.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.86% 42.39% 28.60% -7.00% -30.04% -18.99% -13.94% -10.27% 8.35% -6.11% -14.28%
EBIT Q/Q Growth		 -18.38% 42.39% 28.44% -6.91% -29.75% -18.92% -13.98% -10.36% 8.16% -6.08% -14.43%
NOPAT Q/Q Growth		 -18.38% 42.39% 28.44% -6.91% -29.75% -18.92% -13.98% -10.36% 8.16% -6.08% -14.43%
Net Income Q/Q Growth		 -23.26% 44.45% 29.62% -3.00% -31.51% -13.63% -15.08% -11.58% 10.49% -5.80% -14.80%
EPS Q/Q Growth		 -32.80% 49.19% 30.70% 3.79% -28.80% -7.30% -13.86% -10.87% 15.06% -4.84% -14.73%
Operating Cash Flow Q/Q Growth		 14.93% -55.99% 50.36% 9.53% -86.60% 5.87% -12.76% 10.42% -43.67% 0.94% -2.98%
Free Cash Flow Firm Q/Q Growth		 -27.10% -49.72% 44.00% -9.80% -35.68% -20.35% -51.17% -31.91% -54.07% 19.10% -18.35%
Invested Capital Q/Q Growth		 67.24% 45.79% -22.81% 3.37% 18.66% -18.81% 0.30% -0.30% 14.92% -19.84% -17.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 93.97% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -57.15% -64.41% -185.81% -1,105.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -57.79% -64.84% -187.06% -1,110.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -57.79% -64.84% -187.06% -1,110.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -53.36% -57.51% -172.04% -1,038.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.34% 88.68% 91.97% 93.50% 97.04% 95.75% 100.21% 99.25% 98.16% 100.71% 100.98%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -50.16% -80.35% -129.76% -106.27% -88.78% -123.98% -2,110.28% -352.65% -212.74% -150.12% -223.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -17.64% -13.88% -21.92% -23.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -16.29% -12.31% -20.16% -21.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -50.16% -80.35% -129.76% -106.27% -88.78% -123.98% -2,110.28% -352.65% -212.74% -150.12% -223.17%
Return on Equity Simple (ROE_SIMPLE)		 -55.10% 0.00% -66.74% -59.55% -52.22% 0.00% -1,561.15% -318.63% -209.63% 0.00% -2,567.89%
Net Operating Profit after Tax (NOPAT)		 -56 -47 -81 -114 -106 -82 -69 -61 -55 -60 -56
NOPAT Margin		 -40.45% -45.39% -130.94% -777.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.12% -1.88% -5.09% -6.67% -6.92% -7.29% -26.84% -13.96% -9.48% -9.04% -12.35%
Return On Investment Capital (ROIC_SIMPLE)		 -6.70% -5.38% - - - -15.75% - - - -24.21% -
Cost of Revenue to Revenue		 0.00% 6.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 125.60% 133.99% 176.50% 724.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 32.18% 24.82% 110.56% 485.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 157.79% 158.81% 287.06% 1,210.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -79 -67 -116 -163 -152 -117 -99 -86 -78 -85 -80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -67 -116 -162 -151 -116 -98 -86 -78 -85 -80
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 10.29 8.92 5.93 6.97 6.20 11.27 121.24 40.82 29.27 25.15 104.18
Price to Tangible Book Value (P/TBV)		 10.36 8.98 5.97 7.01 6.23 11.27 121.24 40.82 29.27 25.15 104.18
Price to Revenue (P/Rev)		 23.04 37.36 59.99 407.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 20.74 32.84 48.45 343.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.17 0.16 0.15 0.14 0.14 0.28 5.16 0.96 0.56 0.25 4.59
Long-Term Debt to Equity		 0.17 0.16 0.15 0.14 0.14 0.28 5.16 0.96 0.56 0.25 4.59
Financial Leverage		 -1.07 -1.15 -1.26 -1.19 -1.19 -1.37 -6.74 -1.94 -1.57 -1.47 -1.64
Leverage Ratio		 1.33 1.45 1.64 1.46 1.41 1.66 12.05 2.77 1.88 1.62 1.89
Compound Leverage Factor		 1.23 1.29 1.51 1.36 1.37 1.59 12.07 2.75 1.84 1.63 1.91
Debt to Total Capital		 14.24% 13.48% 13.09% 11.98% 12.01% 22.17% 83.76% 48.95% 35.87% 19.98% 82.11%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 14.24% 13.48% 13.09% 11.98% 12.01% 22.17% 83.76% 48.95% 35.87% 19.98% 82.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 85.76% 86.52% 86.91% 88.02% 87.99% 77.83% 16.24% 51.05% 64.13% 80.02% 17.89%
Debt to EBITDA		 -0.28 -0.24 -0.21 -0.22 -0.26 -0.31 -0.33 -0.30 -0.27 -0.17 -0.18
Net Debt to EBITDA		 1.73 1.64 1.63 1.80 2.09 1.37 0.34 0.61 0.79 1.06 0.38
Long-Term Debt to EBITDA		 -0.28 -0.24 -0.21 -0.22 -0.26 -0.31 -0.33 -0.30 -0.27 -0.17 -0.18
Debt to NOPAT		 -0.40 -0.34 -0.31 -0.31 -0.37 -0.43 -0.47 -0.43 -0.38 -0.24 -0.26
Net Debt to NOPAT		 2.45 2.33 2.31 2.55 2.97 1.95 0.48 0.86 1.12 1.51 0.55
Long-Term Debt to NOPAT		 -0.40 -0.34 -0.31 -0.31 -0.37 -0.43 -0.47 -0.43 -0.38 -0.24 -0.26
Altman Z-Score		 13.75 12.56 7.77 13.26 12.34 9.10 -0.38 7.39 10.15 14.35 -4.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.91 6.10 5.98 8.72 9.39 5.38 2.36 3.02 3.37 3.12 1.59
Quick Ratio		 5.41 5.79 5.79 8.51 9.26 5.35 2.33 2.99 3.35 3.10 1.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -128 -101 -67 -120 -110 -81 -67 -44 -34 -22 -27
Operating Cash Flow to CapEx		 0.00% -53,582.56% -8,598.72% -103,011.45% -41,780.67% -7,715.54% -25,050.15% -109,144.93% -240,191.43% -201,775.86% -178,996.97%
Free Cash Flow to Firm to Interest Expense		 -38.90 -28.85 -18.32 -32.92 -28.57 -20.35 -19.16 -15.31 -14.41 -12.99 -17.98
Operating Cash Flow to Interest Expense		 -26.96 -29.87 -18.21 -36.91 -38.86 -20.13 -24.24 -25.96 -35.99 -34.79 -39.33
Operating Cash Flow Less CapEx to Interest Expense		 -26.96 -29.93 -18.42 -36.95 -38.96 -20.39 -24.33 -25.98 -36.00 -34.81 -39.35
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.31 0.21 0.12 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 174.24 96.25 52.49 13.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.20 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 1,642.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,861.72 2,097.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -219.28 -2,097.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -19 -59 -109 -89 -92 -113 -95 -96 -95 -112 -94
Invested Capital Turnover		 -5.69 -2.09 -0.75 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 73 54 -14 6.60 3.21 -1.22 -1.84 -16 -21 -38 -29
Enterprise Value (EV)		 6,584 5,916 3,721 5,024 4,329 4,049 2,580 4,026 4,149 4,655 1,007
Market Capitalization		 7,314 6,730 4,608 5,971 5,272 4,568 2,698 4,225 4,394 4,964 1,112
Book Value per Share		 $32.18 $34.59 $35.79 $40.22 $42.53 $20.53 $1.20 $5.66 $8.28 $11.54 $0.62
Tangible Book Value per Share		 $31.97 $34.37 $35.57 $39.99 $42.28 $20.53 $1.20 $5.66 $8.28 $11.54 $0.62
Total Capital		 829 872 894 974 967 521 137 203 234 247 60
Total Debt		 118 118 117 117 116 115 115 99 84 49 49
Total Long-Term Debt		 118 118 117 117 116 115 115 99 84 49 49
Net Debt		 -730 -814 -887 -946 -943 -519 -118 -199 -246 -309 -104
Capital Expenditures (CapEx)		 0.00 0.20 0.78 0.13 0.36 1.04 0.34 0.07 0.04 0.03 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -68 -118 -96 -99 -115 -97 -97 -97 -113 -95
Debt-free Net Working Capital (DFNWC)		 821 864 886 967 960 519 136 202 233 245 58
Net Working Capital (NWC)		 821 864 886 967 960 519 136 202 233 245 58
Net Nonoperating Expense (NNE)		 18 13 26 38 41 30 30 25 22 26 25
Net Nonoperating Obligations (NNO)		 -730 -814 -887 -946 -943 -519 -118 -199 -246 -309 -104
Total Depreciation and Amortization (D&A)		 0.87 0.45 0.78 0.74 0.82 0.90 0.81 0.68 0.56 0.44 0.43
Debt-free, Cash-free Net Working Capital to Revenue		 -8.61% -37.53% -153.37% -657.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 258.60% 479.45% 1,153.22% 6,603.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 258.60% 479.45% 1,153.22% 6,603.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.32) ($2.50) ($4.92) ($7.10) ($7.38) ($5.73) ($5.34) ($4.69) ($4.23) ($4.98) ($4.75)
Adjusted Weighted Average Basic Shares Outstanding		 22.09M 21.27M 21.75M 21.40M 20.00M 18.69M 18.48M 18.31M 18.19M 17.14M 17.10M
Adjusted Diluted Earnings per Share		 ($3.32) ($2.50) ($4.92) ($7.10) ($7.38) ($5.73) ($5.34) ($4.69) ($4.23) ($4.98) ($4.75)
Adjusted Weighted Average Diluted Shares Outstanding		 22.09M 21.27M 21.75M 21.40M 20.00M 18.69M 18.48M 18.31M 18.19M 17.14M 17.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.20M 22.08M 21.81M 21.71M 21.31M 19.90M 19.74M 18.47M 18.29M 18.14M 17.10M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -47 -81 -114 -106 -82 -69 -61 -55 -60 -56
Normalized NOPAT Margin		 -40.45% -45.39% -130.94% -777.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -53.36% -57.51% -172.04% -1,038.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -24.06 -19.15 -31.61 -44.46 -39.61 -29.51 -28.12 -29.80 -33.53 -50.71 -53.54
NOPAT to Interest Expense		 -16.84 -13.41 -22.13 -31.12 -27.73 -20.66 -19.68 -20.86 -23.47 -35.50 -37.48
EBIT Less CapEx to Interest Expense		 -24.06 -19.21 -31.82 -44.49 -39.71 -29.77 -28.22 -29.82 -33.55 -50.73 -53.56
NOPAT Less CapEx to Interest Expense		 -16.84 -13.46 -22.34 -31.16 -27.82 -20.92 -19.78 -20.88 -23.49 -35.52 -37.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Madrigal Pharmaceuticals' Financials

When does Madrigal Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Madrigal Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Madrigal Pharmaceuticals' net income changed over the last 9 years?

Madrigal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$465.89 million in 2024, rising from -$68.67 million in 2015. The previous period was -$373.63 million in 2023. See where experts think Madrigal Pharmaceuticals is headed by visiting Madrigal Pharmaceuticals' forecast page.

What is Madrigal Pharmaceuticals's operating income?
Madrigal Pharmaceuticals's total operating income in 2024 was -$497.88 million, based on the following breakdown:
  • Total Gross Profit: $173.90 million
  • Total Operating Expenses: $671.78 million
How has Madrigal Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Madrigal Pharmaceuticals' total revenue changed from $0.00 in 2015 to $180.13 million in 2024, a change of 18,013,300,000.0%.

How much debt does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals' total liabilities were at $287.86 million at the end of 2024, a 22.4% increase from 2023, and a 484.2% increase since 2015.

How much cash does Madrigal Pharmaceuticals have?

In the past 9 years, Madrigal Pharmaceuticals' cash and equivalents has ranged from $306.25 thousand in 2015 to $331.55 million in 2022, and is currently $100.02 million as of their latest financial filing in 2024.

How has Madrigal Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Madrigal Pharmaceuticals' book value per share changed from -0.36 in 2015 to 34.59 in 2024, a change of -9,843.2%.


Related Companies

This page (NASDAQ:MDGL) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored